News Search Results
Mar 25, 2026, 05:38 ET MirZyme Appoints Lindsey Carnett as U.S. Global Ambassador for Women's Health Innovation
MirZyme Therapeutics, a UK-based biotechnology company focused on transforming maternal health, today announced the appointment of
More news about: MirZyme Therapeutics Ltd.
Mar 25, 2026, 05:00 ET Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD
MUNICH, March 25, 2026 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the first patient has been dosed in Opti-GAIN,
More news about: Complement
Mar 25, 2026, 03:24 ET Peptide Therapeutics Market Growing at 7.16% CAGR to Reach USD 70.20 Bn by 2031 Driven by Rising Cancer Prevalence & Metabolic Disorder Burden, Reports Mordor Intelligence
Therapeutics Market Competitive Outlook The peptide therapeutics market features a mix of global pharmaceutical companies and specialized biotechnology firms focusing on innovation, pipeline expansion, and strategic collaborations. Market participants are investing in advanced peptide platforms,
More news about: Mordor Intelligence Private Limited
Mar 24, 2026, 19:50 ET Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced additional positive
More news about: Clover Biopharma
Mar 24, 2026, 19:17 ET uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline
(short video)UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 24, 2026, 16:04 ET WesternU COMP-Northwest Class of 2026 celebrates successful Match Day
Oregon and Pomona, Calif., is an independent nonprofit health professions university, conferring degrees in osteopathic medicine, physical therapy, biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, pharmacy, physician assistant studies, podiatric medicine, and
More news about: Western University of Health Sciences (WesternU)
Mar 24, 2026, 15:05 ET NABR CONDEMNS ALLEGED BREAK-IN AND THEFT AT MIDWEST RESEARCH AND BREEDING FACILITY
research, education, and testing. Members include more than 340 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and
More news about: National Association for Biomedical Research
Mar 24, 2026, 14:00 ET Myosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical Trial
development of innovative cancer therapies and strengthen the life sciences ecosystem in Florida by supporting promising research programs and emerging biotechnology companies. Myosin Therapeutics was selected for funding based on the scientific innovation and clinical potential of MT-125, the company's lead
More news about: Myosin Therapeutics Inc.
Mar 24, 2026, 13:04 ET ZINZINO AB (PUBL): Share subscription due to directed new share issues
of set-off. According to the resolution, 401,965 new Zinzino B shares have been issued by way of set-off of claims against S&M Nano-Biotechnology S.A DE C.V. The transaction is linked to the previously communicated acquisition of assets and subsidiaries of Sanki on November 8, 2025.According
More news about: Zinzino
Mar 24, 2026, 11:18 ET Rubin Rudman Partners Joseph Bodoff and Rion Vaughan Named to 2026 Lawdragon 500 Leading Global Bankruptcy & Restructuring Lawyers
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
Mar 24, 2026, 11:11 ET Pendulum Therapeutics Launches Superfood Gut Fuel Powder
@PendulumLifeCo on Instagram. About Pendulum Therapeutics Pendulum Therapeutics is a biotechnology company pioneering next-generation microbiome innovations designed to improve human health. Founded in 2012 by a team of scientists from Harvard,
More news about: Pendulum Therapeutics
Mar 24, 2026, 10:35 ET PPMD Provides $250,000 in Funding to Secretome Therapeutics Through PPMD Venture Pathways Program to Support Development of Cardiac Cell Therapy
Secretome Therapeutics is a clinical-stage biotechnology company based in Plano, Texas, developing novel therapies derived from neonatal cardiac progenitor cells (nCPCs). Our lead product, STM-01, is a
More news about: Parent Project Muscular Dystrophy (PPMD)
Mar 24, 2026, 10:00 ET Dechert Continues Expansion with Life Sciences and Technology IP Litigators Anish Desai and Priyata Patel
the team and continuing to deliver results in servicing and winning for our clients."Ms. Patel advises clients across the pharmaceutical, biotechnology and medical device industries, with a particular depth in biologics. She leverages her scientific background in biology and her experience as a
More news about: Dechert LLP
Mar 24, 2026, 10:00 ET Threat Hunting Revolution Accelerates with Rapid Adoption of Recorded Future's Autonomous Threat Operations (ATO)
workload."Autonomous Threat Operations (ATO) has become a core part of how we approach modern threat intelligence," according to a global biotechnology company. "By bringing relevant intelligence together and turning it into actionable outcomes, [ATO] has significantly reduced manual effort. Analysts
More news about: Recorded Future
Mar 24, 2026, 09:03 ET Denteric Announces FDA IND Clearance for GPV381, a First-in-Class Therapeutic Vaccine Targeting Gingipain-Driven Inflammation in Periodontitis
intended to enable a disease-modifying approach to the treatment of periodontitis.About DentericDenteric is a clinical-stage biotechnology company developing immunotherapeutic approaches to address the underlying biological drivers of chronic inflammatory diseases.
More news about: Denteric
Mar 24, 2026, 09:02 ET Phenomix Sciences Report Finds Patients See GLP-1s as Progress, Not a Cure; Want More Guidance on Long-Term Care
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today released a new report, "The 2026 State of Obesity Treatment Report: Progress, Gaps, and the Path to Personalized Care," examining
More news about: Phenomix Sciences
Mar 24, 2026, 09:02 ET Vella Bioscience Reveals Bold Rebrand - An Unapologetic Approach to Championing Women's Sexual Vitality and Hormonal Wellness
Inc. is a female health innovator dedicated to advancing women's sexual, hormonal, and intimate wellness through rigorous science and proprietary biotechnology. Built on scientific rigor and developed by the same team behind Viagra® and Cialis®, Vella addresses critical gaps in women's health research with
More news about: Vella Bioscience
Mar 24, 2026, 09:00 ET NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided an update on key regulatory and clinical
More news about: NeuroSense
Mar 24, 2026, 08:24 ET Robert Hollingsworth has been appointed as the Chief Scientific Officer of Protillion Biosciences
American Cancer Society Postdoctoral Fellow at the University of Texas Institute of Biotechnology.About Protillion BiosciencesProtillion Biosciences is an innovative, venture-backed biotechnology company transforming the discovery and development of next-generation therapeutic antibodies.
More news about: Protillion Biosciences, Inc.
Mar 24, 2026, 08:01 ET Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced
More news about: Aethlon Medical, Inc.
Mar 24, 2026, 08:00 ET Argo Biopharma Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
fastcompany.com.About Argo BiopharmaArgo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd
Mar 24, 2026, 08:00 ET Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
Mar 24, 2026, 08:00 ET Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
durable cell-based therapies for T1D a clinical reality.About Continuity BiosciencesContinuity Biosciences is a clinical-stage biotechnology company developing implantable and device-enabled platform technologies at the intersection of drug delivery, biologics, and medical devices. The
More news about: Continuity Biosciences LLC
Mar 24, 2026, 08:00 ET Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
durable cell-based therapies for T1D a clinical reality.About Continuity BiosciencesContinuity Biosciences is a clinical-stage biotechnology company developing implantable and device-enabled platform technologies at the intersection of drug delivery, biologics, and medical devices. The
More news about: Continuity Biosciences LLC
Mar 24, 2026, 07:57 ET RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
resourcesSAN DIEGO, March 24, 2026 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed
More news about: RyboDyn